Company news
Vistagen Therapeutics, Inc. news in 2023
Vistagen Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
December 26, 2023
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
November 8, 2023
Vistagen Announces Pricing of $100 Million Underwritten Offering
October 1, 2023
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
September 11, 2023
Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan
September 4, 2023
Vistagen Appoints Cindy Anderson as Chief Financial Officer
August 21, 2023
Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
August 6, 2023
Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain
July 16, 2023
Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
July 12, 2023
Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results
June 27, 2023
Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023
June 26, 2023
Vistagen Regains Full Compliance with Nasdaq Listing Requirements
June 22, 2023
Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder
June 20, 2023
Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine
June 12, 2023
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes
June 6, 2023
Vistagen Announces Stockholder-Approved Reverse Stock Split
June 5, 2023
Vistagen Receives New European Patent for AV-101
April 5, 2023
Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder
March 21, 2023
Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder
March 7, 2023
Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine
February 28, 2023
Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results
February 6, 2023
Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023
February 5, 2023
Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition
February 1, 2023
Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder
January 23, 2023
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023
January 18, 2023
Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety
January 9, 2023
Calls in 2023
- Vistagen Therapeutics (NASDAQ:VTGN) Q2 2024 Earnings Call
Nov 9, 2023
Transcript - Vistagen Therapeutics (NASDAQ:VTGN) Q1 2024 Earnings Call
Aug 10, 2023
Transcript - Vistagen Therapeutics (NASDAQ:VTGN) Q4 2023 Earnings Call
Jun 28, 2023
Transcript - Vistagen Therapeutics (NASDAQ:VTGN) Q3 2023 Earnings Call
Feb 7, 2023
Transcript
Decks in 2023
- Investor Presentation (October 2023)
Investor deck · 62 slides · Oct 4, 2023
- Investor Presentation (September 2023)
Investor deck · 57 slides · Sep 8, 2023